There are 300,000 coronary angioplasty procedures performed annually. Of these, 12 to 34 percent of the cases consistently result in restenosis and the need to re-open or bypass the occluded portion of the vessel. One of the primary causes of re-stenosis is the accumulation of platelets in the area denuded by angioplasty which in turn produce platelet derived growth factor, ad strong chemoattractant for smooth muscle cells. The accumulation of smooth muscle cells leads to hyperplasia and ultimately to occlusion of the vessel. The proposed research is directed at developing a system to re-seed the denuded portion of the vessel with autologous endothelial cells to circumvent the accumulation of platelets. This will be done by developing a cell seeding matrix designed to suspend cells in during the seeding process and a cell delivery system. The developed matrix and delivery system will be tested in an in vitro perfusion loop (Phase I) followed by in vivo application (Phase II) in a denuded canine artery. This will require developing a seeding matrix that will enhance cell attachment to the denuded vessel and testing the cell seeding system for delivery of the cells to the denuded vessel. This research has commercial application in the field of interventional cardiovascular medicine and application to other vascular diseases is highly conceivable.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL044765-01
Application #
3501775
Study Section
Special Emphasis Panel (SSS (B1))
Project Start
1990-05-15
Project End
1990-11-14
Budget Start
1990-05-15
Budget End
1990-11-14
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Endotech Corporation
Department
Type
DUNS #
City
Indianapolis
State
IN
Country
United States
Zip Code
46268